Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitogen-activated protein kinase kinase kinase 21 (MAP3K21) is a serine/threonine protein kinase and part of the MAP kinase kinase kinase (MAP3K) family. It acts as a negative regulator of TLR4 signaling and is involved in the regulation of signal transduction pathways, particularly those controlling immune responses. MAP3K21 is not known to activate the JNK, p38, or ERK2 MAPK pathways. It is predicted to have protein autophosphorylation and protein homodimerization activities, and is predominantly localized in the cytoplasm. The protein has been implicated in the pathogenesis of certain cancers (notably colorectal cancer, where it cooperates with activated RAS signaling to drive tumorigenesis) and as an immune marker in specific cancer subtypes[1][3][6][5]. No interacting drugs or significant safety concerns have been documented in the referenced sources.
Inhibition of kinase activity, Modulation of MAPK signaling pathways, Negative regulation of TLR4 signaling
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitogen-activated protein kinase kinase kinase 21 (MAP3K21).